Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors Article

Lassman, Andrew B, Hoang-Xuan, Khe, Polley, Mei-Yin C et al. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors . JOURNAL OF CLINICAL ONCOLOGY, 40(23), 2539-+. 10.1200/JCO.21.02543

Open Access International Collaboration

cited authors

  • Lassman, Andrew B; Hoang-Xuan, Khe; Polley, Mei-Yin C; Brandes, Alba A; Cairncross, J Gregory; Kros, Johan M; Ashby, Lynn S; Taphoorn, Martin JB; Souhami, Luis; Dinjens, Winand NM; Laack, Nadia N; Kouwenhoven, Mathilde CM; Fink, Karen L; French, Pim J; Macdonald, David R; Lacombe, Denis; Won, Minhee; Gorlia, Thierry; Mehta, Minesh P; van den Bent, Martin J

sustainable development goals

authors

publication date

  • August 10, 2022

published in

keywords

  • ADJUVANT PROCARBAZINE
  • BENEFIT
  • CLASSIFICATION
  • EUROPEAN ORGANIZATION
  • FOLLOW-UP
  • GLIOBLASTOMA
  • Life Sciences & Biomedicine
  • NOA-04
  • Oncology
  • SURVIVAL
  • Science & Technology
  • TEMOZOLOMIDE

Digital Object Identifier (DOI)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

start page

  • 2539

end page

  • +

volume

  • 40

issue

  • 23